-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Hebei Provincial Commission for Discipline Inspection Conducts Research and Provides Guidance on the Implementation of Prevention and Control Measures and Production Assurance at Shisi Pharmaceutical
Category:
发布时间：2020-01-30
【概要描述】
On the afternoon of January 29, relevant officials from the Hebei Provincial Commission for Discipline Inspection conducted an on-site inspection and provided guidance at Shijiazhuang No. 4 Pharmaceutical Co., Ltd. on the implementation of epidemic prevention and control measures and the assurance of production and supply.
On the afternoon of January 29, relevant officials from the Hebei Provincial Commission for Discipline Inspection conducted an on-site inspection and provided guidance at Shijiazhuang No. 4 Pharmaceutical Co., Ltd. on the implementation of epidemic prevention and control measures and the assurance of production and supply. “We must support enterprises in accelerating production, rigorously and meticulously implementing epidemic prevention and control measures, and ensure that no outbreaks occur within the company while maintaining a reliable supply of products.”
Relevant officials from the Provincial Commission for Discipline Inspection conducted a detailed briefing with Wu Hengyao, General Manager of Shijiazhuang No. 4 Pharmaceutical, on the implementation of the company’s epidemic prevention and control measures and the assurance of production factors. The officials commended the company highly for its proactive implementation of epidemic prevention measures, its ability to overcome difficulties and ramp up production, its effective organization of emergency drug supplies to support frontline efforts in pandemic control, and its commitment to corporate social responsibility—demonstrating, at a critical moment, the mission and sense of responsibility that define pharmaceutical enterprises.
Relevant officials from the Provincial Commission for Discipline Inspection stated that they must respond promptly to the urgent needs of production enterprises, fulfill their role in supporting normal production operations, and resolutely win the battle against the epidemic.
Relevant officials from the Discipline Inspection Commission of Shijiazhuang City and the Discipline Inspection Commission of the Shijiazhuang High-tech Industrial Development Zone attended the research visit.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091